Breaking News

Grünenthal Acquires US-based Thar Pharmaceuticals

Expands its development portfolio for complex regional pain syndrome

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, has acquired Thar Pharmaceuticals, a U.S.-based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology Enhance development platform. With this acquisition, Grünenthal has obtained the worldwide development and commercialization rights for Thar Pharmac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters